TABLE 3.
Overview of Participants in the CARRA Registry (February 2013)
| Number of Participants | % Current or Previous Exposure to Biologicsa | % Current or Previous Exposure to DMARDS or Immune Suppressive Medicationsb | |
|---|---|---|---|
| Total number enrolled | 8211 | 34.5 | 75.9 |
| Specific diagnosesc | |||
| JIA | 5823 | 42.9 | 72.3 |
| SLE | 834 | 11.5 | 95.1 |
| Mixed connective tissue disease | 141 | 23.4 | 92.9 |
| Juvenile dermatomyositis | 552 | 11.2 | 94.4 |
| Vasculitis | 170 | 27.1 | 82.4 |
| Systemic sclerosis | 48 | 2.1 | 87.5 |
| Localized scleroderma | 316 | 2.9 | 86.7 |
| Sjogren syndrome | 16 | 18.8 | 81.3 |
| Autoinflammatory disease | 52 | 25.0 | 23.1 |
| Idiopathic uveitis | 70 | 55.7 | 82.9 |
| Sarcoidosis | 45 | 53.3 | 77.8 |
| Pain syndromes | 144 | 2.1 | 5.6 |
DMARDS, disease-modifying antirheumatic drugs; SLE, systemic lupus erythematosus.
a
Includes abatacept, adalimumab, anakinra, belimumab, canakinumab, certolizumab, etanercept, golimumab, infliximab, rilonacept, rituximab, and tocilizumab. Excludes intravenous immunoglobulin.
b
Includes azathioprine, cyclophosphamide, cyclosporine, hydroxychloroquine, leflunomide, methotrexate, mycophenylate mofetil, sulfasalazine, and tacrolimus. Excludes corticosteroids.
c
Additional diagnoses added as of February 2, 2012 include Sjogren syndrome, autoinflammatory diseases, and idiopathic uveitis.